Abzena agrees to be taken over by US private equity firm WCAS
16th Aug 2018 10:18
(Sharecast News) - Abzena has agreed to be taken over by US private equity firm WCAS in a £34.4m deal.
Read moreAbzena signs licensing agreement for 'ThioBridge' technology
20th Jan 2017 10:29
(ShareCast News) - Life sciences group Abzena announced on Friday that it has signed a licensing agreement with an unnamed San Diego-based biopharmaceutical company for its site-specific 'ThioBridge' antibody drug conjugate linker technology. The AIM-traded company said 'ThioBridge' links antibodies
Read moreAbzena inks licence agreement with Trieza Therapeutics
22nd Dec 2016 14:20
(ShareCast News) - Life-sciences group Abzena has inked a licence agreement with start-up biotechnology company Trieza Therapeutics. US-based Trieza specialises in the discovery and development of immunomodulatory oncolytic viruses. Abzena has granted Trieza an exclusive licence to an undisclosed a
Read moreAbzena shares plunge as Gilead drops simtuzumab
2nd Nov 2016 14:11
(ShareCast News) - Life sciences group Abzena noted on Wednesday that during Gilead Sciences' announcement of third quarter earnings on 1 November, it stated that no further development of simtuzumab will be pursued. The AIM-traded firm also noted that GS-5745 will not be progressed further by Gilea
Read moreAbzena notes progress with Composite Human Antibody tech
21st Oct 2016 13:47
(ShareCast News) - Life sciences group Abzena noted on Friday that Gilead Sciences has announced top line Phase II clinical study results of its product, GS-4997 (selonsertib) in combination with the investigational monoclonal antibody, simtuzumab (SIM) or SIM alone, in patients with non-alcoholic s
Read moreAbzena highlights Roche's acquisition of Adheron Therapeutics
9th Oct 2015 12:41
(ShareCast News) - Life sciences company Abzena announced that Roche has acquired Adheron Therapeutics, which is a privately-held biotechnology company developing the SPD051 product that disrupts cell adhesion using Abzena's Composite Human Antibody technology. Adheron has completed a Phase I study
Read moreAbzena completes PacificGMP deal
14th Sep 2015 11:43
(ShareCast News) - Life sciences group Abzena has completed the acquisition of biopharmaceutical development and manufacturing company PacificGMP for $7.7m in cash and stock. In a statement released on Monday, the company said the acquisition will be financed by existing cash resources and by the is
Read more